Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. stock (symbol: QNRX) underwent a total of 4 stock splits.
The most recent stock split occured on Jul 18, 2023.
Date | Splite | Multiple |
---|---|---|
2023-07-18 | 1:12 | 1 |
2022-08-01 | 8:100 | 8 |
2021-09-24 | 1:4 | 1 |
2019-10-23 | 1:5 | 1 |